HPV vaccine given to young women may also protect similarly-aged men against oropharyngeal cancers, which have been rising in incidence in the U.S. and Western Europe. In a small study in the UK, rates of oral HPV infections caused by HPV-16 were similar for males 12-24 years of age and vaccinated females (0% vs. 0.5%). This was considerably lower than the rates for unvaccinated females (5.6%) and men ≥25 years old (7.1%).
HPV-16 is the main HPV type linked to oropharyngeal cancers.
Full Citation:
Mehanna H, Bryant TS, Babrah J et al.. 2018. Human papillomavirus (HPV) vaccine effectiveness and potential herd immunity for reducing oncogenic oropharyngeal HPV-16 prevalence in the United Kingdom: A cross-sectional study. Clinical Infectious Diseases. 69(8).
Title of Article: Human papillomavirus (HPV) vaccine effectiveness and potential herd immunity for reducing oncogenic oropharyngeal HPV-16 prevalence in the United Kingdom: A cross-sectional study
Author(s): Mehanna H, Bryant TS, Babrah J et al.
Publication Year: 2018
Publication Name: Clinical Infectious Diseases
Publication Volume: 69(8)
Publication Source URL: https://pubmed.ncbi.nlm.nih.gov/30590469/
DOI (Digital Object Identifier): 10.1093/cid/ciy1081
Topics: Health
Disease Vaccines: Human papillomavirus (HPV)
Countries: United Kingdom
WHO Regions: Europe